EU drugs watchdog begins review of Moderna's variant COVID vaccine

The European Medicines Agency (EMA) started a rolling review on Friday of a variant-adapted COVID-19 vaccine from Moderna (MRNA.O), as coronavirus cases linked to Omicron sub-variants see an uptick in the region. U.S.-based Moderna's so-called bivalent vaccine targets two strains of the SARS-CoV-2 virus behind COVID, the original strain first identified in China, and the Omicron variant. Last week, Moderna said its bivalent vaccine produced a better immune response against Omicron than the original shot.